A diabetes drug company is lobbying the Sask. government as Ottawa recommits to pharmacare – CTV
May 15, 2025
An international pharmaceutical company and a diabetes charity have registered to lobby the Saskatchewan government to expand coverage of medication and support for the chronic illness.
Last week, Eli Lilly — a major manufacturer — registered to lobby the province’s government to have its drugs publicly listed and reimbursed, and about “pan-Canadian pharmaceutical policy and pricing programs and initiatives; health system partnerships; pharmacare.”
The company creates drugs to address a range of issues, from cancer to arthritis and diabetes.
Under the national pharmacare program, certain diabetes and contraceptive drugs are covered by the federal government, including some of Eli Lilly’s insulin products.
During the federal election campaign, the Liberal Party promised to continue signing deals with provinces to implement the federal plan.
Before the election was called, Health Canada had negotiated deals with Prince Edward Island, Manitoba, Yukon and B.C. while Alberta and Quebec planned to opt out of the program.
